INKT vs. CYAD, CELU, ATRA, ACET, MOLN, CRDF, LIFE, SGMO, DBVT, and OMGA
Should you be buying MiNK Therapeutics stock or one of its competitors? The main competitors of MiNK Therapeutics include Celyad Oncology (CYAD), Celularity (CELU), Atara Biotherapeutics (ATRA), Adicet Bio (ACET), Molecular Partners (MOLN), Cardiff Oncology (CRDF), aTyr Pharma (LIFE), Sangamo Therapeutics (SGMO), DBV Technologies (DBVT), and Omega Therapeutics (OMGA). These companies are all part of the "medical" sector.
MiNK Therapeutics (NASDAQ:INKT) and Celyad Oncology (NASDAQ:CYAD) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their community ranking, institutional ownership, media sentiment, dividends, analyst recommendations, earnings, risk, profitability and valuation.
MiNK Therapeutics currently has a consensus price target of $9.00, suggesting a potential upside of 833.37%. Given MiNK Therapeutics' higher possible upside, analysts plainly believe MiNK Therapeutics is more favorable than Celyad Oncology.
2.9% of MiNK Therapeutics shares are held by institutional investors. 17.8% of MiNK Therapeutics shares are held by company insiders. Comparatively, 0.9% of Celyad Oncology shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.
Celyad Oncology received 274 more outperform votes than MiNK Therapeutics when rated by MarketBeat users. However, 68.75% of users gave MiNK Therapeutics an outperform vote while only 67.70% of users gave Celyad Oncology an outperform vote.
In the previous week, MiNK Therapeutics had 1 more articles in the media than Celyad Oncology. MarketBeat recorded 1 mentions for MiNK Therapeutics and 0 mentions for Celyad Oncology. MiNK Therapeutics' average media sentiment score of 0.00 equaled Celyad Oncology'saverage media sentiment score.
Celyad Oncology has higher revenue and earnings than MiNK Therapeutics.
Summary
MiNK Therapeutics beats Celyad Oncology on 6 of the 10 factors compared between the two stocks.
Get MiNK Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for INKT and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding INKT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
MiNK Therapeutics Competitors List
Related Companies and Tools
